Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 13/20 | 0.42 |
| ▸ | RORC | P51449 | 6/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21030783 | 1.00 | BDKRB2 (0.42) | BDKRB2RORCCYP3A4CYP2C19MAPK1 | |
| SCHEMBL22334224 | 0.95 | BDKRB2 (0.44) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL21030790 | 0.90 | BDKRB2 (0.40) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL22662459 | 0.90 | BDKRB2 (0.40) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL21030331 | 0.90 | BDKRB2 (0.43) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL21030330 | 0.90 | BDKRB2 (0.43) | BDKRB2RORC | |
| SCHEMBL22334227 | 0.90 | BDKRB2 (0.44) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL22334230 | 0.90 | BDKRB2 (0.44) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL21030795 | 0.89 | BDKRB2 (0.43) | BDKRB2RORCCYP3A4CYP2C19 | |
| SCHEMBL21030782 | 0.89 | BDKRB2 (0.42) | BDKRB2RORCCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2023-11-21 | — | — | US | disclosed |
| EP-3998259-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-18 | — | — | EP | disclosed |
| US-20220135543-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | Pharvaris Netherlands B.V. (NL) | 2022-05-05 | — | — | US | disclosed |
| EP-3713928-B1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | PHARVARIS NETHERLANDS B V (NL) | 2022-01-12 | — | — | EP | disclosed |
| US-20210017158-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10836748-B2 | Bradykinin B2 receptor antagonists | Pharvaris Netherlands B.V. (NL) | 2020-11-17 | — | — | US | disclosed |
| US-20200255405-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | ANALYTICON DISCOVERY GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017158-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4082/4885CYP3A4 2143/4885 |
| US-20220135543-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4082/4885CYP3A4 2143/4885 |
| US-10836748-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4230/4885CYP3A4 1840/4885 |
| US-11820756-B2 | Bradykinin B2 receptor antagonists | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4230/4885CYP3A4 1840/4885 |
| US-20200255405-A1 | NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS | BDKRB2, BDKRB1, VIPR2 | BDKRB2 1/4885RORC 4082/4885CYP3A4 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.